Victory Capital Management
LRMR icon

Victory Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Victory Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-442
Closed -$4K – 2930
2020
Q1 		$4K Buy
+442
New +$5.81K ﹤0.01% 3357
2019
Q4 		– Sell
-470
Closed -$4K – 2985
2019
Q3 		$4K Buy
+470
New +$5.15K ﹤0.01% 3508

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Victory Capital Management's LRMR Position: Q2 2020 in Review

Victory Capital Management sold out of Larimar Therapeutics (LRMR) in Q2 2020, closing a stake of 442 shares — an estimated $4K sold.

Victory Capital Management first reported a position in LRMR in Q3 2019 and held it in 2 quarters. The position peaked at $4K in Q1 2020. 37 funds tracked by Wall St. Rank hold LRMR as of Q2 2020.

  • Victory Capital Management reported no remaining Larimar Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 442 Larimar Therapeutics shares in Q2 2020, an estimated $4K.
  • Victory Capital Management first reported a position in Larimar Therapeutics in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Larimar Therapeutics position peaked at $4K in Q1 2020.
  • 37 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.